Zydus Cadila gets USFDA nod to market alcohol abstinence drug

Drug firm Zydus Cadila has received approval from the US health regulator to market Acamprosate calcium delayed-release tablets used for maintenance of abstinence from alcohol in the US market.

"Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Acamprosate calcium delayed-release tablets, 333 mg", Cadila Healthcare said in a BSE filing.

The drug will be produced at the group's formulations manufacturing facility at Baddi, it added.

"This medication is used for maintenance of abstinence from alcohol in patients with alcohol dependence", Cadila Healthcare said.

The group now has more than 115 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since the commencement of the filing process in financial year 2003 -04, it added.

(This article has not been edited by DNA's editorial team and is auto-generated from an agency feed.)